<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570072</url>
  </required_header>
  <id_info>
    <org_study_id>CAUDepression-02</org_study_id>
    <nct_id>NCT04570072</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic on Comorbidity of Depression and Constipation</brief_title>
  <official_title>Effect of Probiotic on Chinese Patients With Depression and Constipated Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Agricultural University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Agricultural University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depressive disorder, also known as depression, is a type of mood disorder characterized by&#xD;
      persistent low mood. The incidence of depression worldwide is about 6%. The high comorbidity&#xD;
      rate between depression and constipation indicated the role of the gut-brain axis in&#xD;
      depression. Growing evidence suggested that the gut microbiota plays a key role in the&#xD;
      development of depression. Probiotics can effectively improve constipation and regulate gut&#xD;
      microbiota, and showed potential in alleviating depression. This study investigated the&#xD;
      effect of formula probiotic (containing Lactobacillus paracasei, Bifidobacterium animals,&#xD;
      Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum) on the&#xD;
      comorbidity of depression and constipation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Change from baseline score to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Depressive symptoms as measured with the Hamilton Rating Scale for Depression. The score rangs from 0 to 53. The higher score means severer depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptom</measure>
    <time_frame>changes from baseline score to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Constipation symptoms as measured with the Patient Assessment of Constipation Symptom. The score ranges from 0 to 48. The higher score means severer constipated symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Il-1β</measure>
    <time_frame>changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum Il-1β levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Il-6</measure>
    <time_frame>changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum Il-6 levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum TNF-α</measure>
    <time_frame>changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum TNF-α levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol</measure>
    <time_frame>changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum cortisol levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Brain-derived neurotrophic factor</measure>
    <time_frame>changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum Brain-derived neurotrophic factor levels before and after intervention assessed by ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of tryptophan metabolites</measure>
    <time_frame>Changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Serum concentrations of tryptophan metabolites quantified by High-Performance Liquid Chromatography and Mass Spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of bile acid</measure>
    <time_frame>Changes from baseline level to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Quantification by High-Performance Liquid Chromatography and Mass Spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome</measure>
    <time_frame>Changes from baseline to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Fecal microbiome measured by next generation sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool form</measure>
    <time_frame>Change from baseline score to intervention measurements at 4 and 8 weeks</time_frame>
    <description>Stool form measured with the Bristol Stool Form Scale, which classify the form of human faeces into seven types, successively named type 1 to type 7. Types 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 indicating lack of dietary fiber, and 6 and 7 indicate diarrhoea.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Comorbidity of Depression and Constipation</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formula probiotic contains freeze-dried Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum, each at a dosage of 3.0 × 10^10 colony forming unit per 2g sachet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo made with only the excipients. The placebo sachet was matched to the study probiotic products for taste, color, and size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal body mass index ≥ 18.5 until ≤ 29.9&#xD;
&#xD;
          -  Hamilton Rating Scale for Depression (HAMD-17) score not less than 8&#xD;
&#xD;
          -  Meet the ROME III criteria for functional constipation&#xD;
&#xD;
          -  Agreed to intake study product during the study period&#xD;
&#xD;
          -  Agreed to sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic antibiotics or antimycotics medication in the 30 days prior to the&#xD;
             study&#xD;
&#xD;
          -  Investigator's uncertainty about the willingness or ability of subject to comply with&#xD;
             the protocol requirements&#xD;
&#xD;
          -  Persons with a milk protein allergy, lactose intolerance&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Subject had other serious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fazhen Ren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Agricultural University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fazheng Ren, PhD</last_name>
    <phone>+86-10-62736344</phone>
    <email>renfazheng@cau.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xifan Wang, PHD</last_name>
    <email>wangxfan@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Ni, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90.</citation>
    <PMID>21791035</PMID>
  </reference>
  <reference>
    <citation>Walker EA, Katon WJ, Jemelka RP, Roy-Bryne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study. Am J Med. 1992 Jan 24;92(1A):26S-30S.</citation>
    <PMID>1531168</PMID>
  </reference>
  <reference>
    <citation>Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016 Nov 3;167(4):915-932. doi: 10.1016/j.cell.2016.10.027. Review.</citation>
    <PMID>27814521</PMID>
  </reference>
  <reference>
    <citation>De Palma G, Blennerhassett P, Lu J, Deng Y, Park AJ, Green W, Denou E, Silva MA, Santacruz A, Sanz Y, Surette MG, Verdu EF, Collins SM, Bercik P. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat Commun. 2015 Jul 28;6:7735. doi: 10.1038/ncomms8735.</citation>
    <PMID>26218677</PMID>
  </reference>
  <results_reference>
    <citation>Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, Ota M, Koga N, Hattori K, Kunugi H. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord. 2016 Sep 15;202:254-7. doi: 10.1016/j.jad.2016.05.038. Epub 2016 May 24.</citation>
    <PMID>27288567</PMID>
  </results_reference>
  <results_reference>
    <citation>Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Review. Erratum in: Ann Gen Psychiatry. 2017 Mar 7;16:18.</citation>
    <PMID>28239408</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019 Apr;38(2):522-528. doi: 10.1016/j.clnu.2018.04.010. Epub 2018 Apr 24.</citation>
    <PMID>29731182</PMID>
  </results_reference>
  <results_reference>
    <citation>Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016 Mar;32(3):315-20. doi: 10.1016/j.nut.2015.09.003. Epub 2015 Sep 28.</citation>
    <PMID>26706022</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Agricultural University</investigator_affiliation>
    <investigator_full_name>Fazheng Ren</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

